Hunan Jiudian Pharmaceutical Co Ltd banner

Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705

Watchlist Manager
Hunan Jiudian Pharmaceutical Co Ltd Logo
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Watchlist
Price: 12.85 CNY -0.7% Market Closed
Market Cap: ¥6.4B

P/S

2.1
Current
31%
Cheaper
vs 3-y average of 3

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
2.1
=
Market Cap
¥7.7B
/
Revenue
¥3.1B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
2.1
=
Market Cap
¥7.7B
/
Revenue
¥3.1B

Valuation Scenarios

Hunan Jiudian Pharmaceutical Co Ltd is trading below its 3-year average

If P/S returns to its 3-Year Average (3), the stock would be worth ¥18.55 (44% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+87%
Average Upside
51%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 2.1 ¥12.85
0%
3-Year Average 3 ¥18.55
+44%
5-Year Average 3 ¥18.11
+41%
Industry Average 3.9 ¥24
+87%
Country Average 2.8 ¥16.86
+31%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
¥7.7B
/
Oct 2025
¥3.1B
=
2.1
Current
¥7.7B
/
Dec 2025
¥3.6B
=
2.2
Forward
¥7.7B
/
Dec 2026
¥4.1B
=
1.9
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
CN
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
6.4B CNY 2.1 13.7
US
Eli Lilly and Co
NYSE:LLY
910.2B USD 14 44.1
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 5.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.2 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 4.7 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 5 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 4.3 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 2.4 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
117.2B USD 2.4 16.6

Market Distribution

In line with most companies in China
Percentile
41st
Based on 7 736 companies
41st percentile
2.1
Low
0 — 1.5
Typical Range
1.5 — 5.4
High
5.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.8
70th Percentile 5.4
Max 5 034 353.9

Hunan Jiudian Pharmaceutical Co Ltd
Glance View

Market Cap
6.4B CNY
Industry
Pharmaceuticals

Hunan Jiudian Pharmaceutical Co Ltd, nestled amidst the vibrant commercial landscape of China, exemplifies the dynamic evolution of the pharmaceutical industry within the region. Founded on the principles of innovation and resilience, the company has carved a niche by focusing on the development, production, and sale of a variety of active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates through an intricate web of research and development that is deeply aligned with the latest advancements in medical science. Central to its operations is a robust R&D facility that not only ensures high-standard quality control but also keeps the pipeline brimming with potential new products. This forward-thinking approach is critical, as it continually feeds the market with pharmaceuticals that cater to both chronic and acute health conditions, ranging from anti-infectives to cardiovascular drugs. The company capitalizes on a vertically integrated business model, which substantially aids in controlling cost and quality across all stages of production. By managing a seamless supply chain that extends from raw material procurement to drug distribution, Hunan Jiudian Pharmaceutical ensures both operational efficiency and market competitiveness. Revenue streams largely flow from the sale of its proprietary products in domestic and international markets, supported by a comprehensive marketing strategy and a broad distribution network. This pragmatic blend of science, strategy, and salesmanship allows the company not only to generate profits but also to contribute significantly to the global pharmaceutical framework, marking its presence as a formidable player in this ever-changing industry.

Intrinsic Value
11.83 CNY
Overvaluation 8%
Intrinsic Value
Price ¥12.85
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett